Risedronate in the treatment of paget's disease of bone: An open label, multicenter study

Journal of Bone and Mineral Research

Volumn 13, Issue 6, 1998, Pages 1032-1038

  Siris, Ethel S ^a   Chines, Arkadi A ^b   Altman, Roy D ^c   Brown, Jacques P ^d   Johnston Jr , C Conrad ^e   Lang, Robert ^f   Mcclung, Michael R ^g   Mallette, Lawrence E ^h   Miller, Paul D ⁱ   Ryan, Will G ^j   Singer, Frederick R ^k   Tucci, Joseph R ^a   Eusebio, Rachelle A ^b   Bekker, Pirow J ^b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITÉ LAVAL   (Canada)

^e INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^f Earle A Chiles Research Institute ^*

^g MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h University of Colorado Health Sciences Center   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j JOHN WAYNE CANCER INSTITUTE   (United States)

^k ROGER WILLIAMS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCITONIN; CALCITRIOL; CALCIUM; ETIDRONIC ACID; MITHRAMYCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHORUS; RISEDRONIC ACID; TILUDRONIC ACID; VINBLASTINE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE PAIN; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; URINARY EXCRETION; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; CALCIUM CHANNEL BLOCKERS; CAPSULES; DELAYED-ACTION PREPARATIONS; ETIDRONIC ACID; FEMALE; GELATIN; HUMANS; MALE; MIDDLE AGED; OSTEITIS DEFORMANS;

EID: 15144345644     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.6.1032     Document Type: Article

References (29)

1. Kanis JA 1991 Pathophysiology and Treatment of Paget's Disease of Bone. Carolina Academic Press, Martin Dunitz, London, U.K.
2. Delmas PD, Meunier PJ 1997 The management of Paget's disease of bone. N Engl J Med 336:559-566.
3. Siris ES 1994 Extensive personal experience: Paget's disease of bone. J Clin Endocrinol Metab 80:335-338.
4. Geddes AD, D'Souza SS, Ebetino FH, Ibbotson KJ 1994 Bisphosphonates: Structure-activity relationships and therapeutic implications. In: Heersche JNM, Kanis JA (eds.) Bone and Mineral Research. Elsevier Science BV, New York, NY, U.S.A., pp. 265-306.
5. McOsker J, Sietsema WK 1990 Preclinical pharmacology of risedronate, a third generation bisphosphonate. J Bone Miner Res 5 (Suppl 2): 105.
6. Roux C, Ravaud M, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, Delmas P, Dougados M, Amor B 1994 Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15: 41-49.
7. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy G 1993 Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 77:1067-1071.
8. Brown JP, Kylstra JW, Bekker PJ, Axelrod DW, Siris ES, Altman RD, Singer FR 1994 Risedronate in Paget's disease: Preliminary results of a multicenter study. Semin Arthritis Rheum 23:272.
9. Kylstra JW, Bekker PJ, Clemens TL, Valentin-Opran A, Axelrod DW, Singer FR 1992 Risedronate in resistant Paget's disease of bone. Bone Miner 17 (Suppl 1):209.
10. Mitchell DY, Eusebio RA, Dunlap LE, Nesbitt JD, Russell DA, Clay ME, Bekker PJ 1996 Bioavailability of immediaterelease and delayed-release risedronate formulations upon oral administration to healthy male subjects in fasted and fed state. Pharm Res 13:S458.
11. Kanis JA, Gray RES 1987 Long-term follow-up observations on treatment in Paget's disease of bone. Clin Orthop 217:99-125.
12. Meunier PJ, Vignot E 1995 Therapeutic strategy in Paget's disease of bone. Bone 17 (Suppl 1):489-491.
13. McClung MR, Tou CKP, Goldstein NH, Picot C 1995 Tiludronate therapy for Paget's disease of bone. Bone 17 (Suppl 1):493-496.
14. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse HP, Picot C, Titeux L, Reginster JY, Dougados M 1995 Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 38:851-858.
15. Reid IR, NicholsonGC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA Jr, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, YatesAJ 1996 Biochemical and radiologie improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med 171:341-348.
16. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA Jr, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M 1996 Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81:961-967.
17. Stone MD, Hawthorne AB, Kerr D, Webster G, Hosking DJ 1990 Treatment of Paget's disease with intermittent low-dose infusion of disodium pamidronate (APD). J Bone Miner Res 5:1231-1235.
18. Hosking DJ 1981 Calcitonin and diphosphonate in the treatment of Paget's disease of bone. Metab Bone Dis Rel Res 3:317-326.
19. Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafini AN, Sankey RR 1973 Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 289:1379-1384.
20. Khairi MRA, Altman RD, DeRosa GP, Zimmermann J, Schenk RK, Johnston CC 1977 Sodium etidronate in the treatment of Paget's disease of bone: A study of long-term results. Ann Intern Med 87:656-663.
21. Bekker PJ, Adachi JD, Brown JP, Khairi RA, Licata AA, McClung MR, Ryan WG, Siris ES, Tenenhouse A, Wallach S, Axelrod DW 1997 Risedronate treatment improves pain status in patients with Paget's disease of bone. J Bone Miner Res 12 (Suppl 1):S270.
22. Hosking DJ, Eusebio RA, Chines AA 1998 Paget's disease of bone: Reduction of disease activity with oral risedronate. Bone 22:51-55.
23. Delmas PD, Chapuy MC, Vignon E, Briancon D, Edouard C, Meunier PJ 1982 Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab 54:837-844.
24. Siris ES, Canfield RE, Jacobs TP, Bacquiran DC 1980 Long-term therapy of Paget's disease of bone with EHDP. Arthritis Rheum 23:1177-1184.
25. Walton RJ, Russell RGG, Smith R 1975 Changes in the renal and extra-renal handling of phosphate induced by disodium etidronate in man. Clin Sei Mol Med 49:45-56.
26. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK 1996 Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021.
27. Siris ES 1993 Bisphosphonates and iritis. Lancet 341:436-437 (letter).
28. O'Donnell NP, Rao GP, Aguis-Fernandez A 1995 Paget's disease: Ocular complications of disodium pamidronate treatment. Br J Clin Pract 49:272-273.
29. Macarol V, Fraunfelder FT 1994 Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118: 220-224.